ACCESS Newswire

ZeroPath Corp. Launches Next-Generation Code Security Platform Powered by Artificial Intelligence

22.1.2025 03:00:00 CET | ACCESS Newswire | Press release

Share

ZeroPath Security Scanner Launches to Market, Bringing Enterprise-Grade AI Security Analysis to Development Teams

SAN FRANCISCO, CA / ACCESS Newswire / January 22, 2025 / ZeroPath Corp., a Y Combinator-backed cybersecurity company, today announced the public launch of its LLM-driven code security platform. The company was previously noted for using its platform to find critical zero-day vulnerabilities in major open-source projects. Alongside the launch, the company also announced the completion of its seed funding round led by SurgePoint Capital, with Y Combinator and angel investor Paul Graham both participating.

null

ZeroPath's security testing platform, among the first of its kind, attempts to combine deep program analysis with large language models to detect more complex security vulnerabilities. The system has previously demonstrated remarkable success in identifying critical security flaws in large open-source repositories, including remote code execution vulnerabilities, authorization bypasses, and business logic flaws.

"Traditional security tools often rely on pattern matching and predefined rules, which can miss complex vulnerabilities that don't fit known patterns," said Raphael Karger, CTO of ZeroPath. "Our platform's ability to understand context and business logic allows it to identify sophisticated security issues that would typically require manual code review by expert security researchers."

Unusual for the application security industry, the platform does not rely on rule-based detection of code security problems; instead, it uses large language models to scan large swaths of code and validate potential vulnerabilities before reporting them. The company's approach has proven particularly effective in discovering business logic flaws and authentication vulnerabilities that traditionally require extensive manual review to identify. The approach has also been touted for its ability to provide a lower false positive rate than traditional static analysis tools.

For more information about ZeroPath's AI-powered security platform, visit https://www.zeropath.com

About ZeroPath Corp.: ZeroPath Corp. is a San Francisco-based cybersecurity company that combines artificial intelligence with deep program analysis to detect complex security vulnerabilities. The company's innovative approach to security testing has already uncovered critical vulnerabilities in major open-source projects, helping secure code used by millions of users worldwide.

Contact Information

Media Contact
Name: Raphael Karger
Email: press@zeropath.com
Phone: +1 ‪(617) 431-6720

Social Media:
LinkedIn: https://www.linkedin.com/company/zeropathai
X (Twitter): https://x.com/zeropathAI

SOURCE: ZeroPath Corp.



View the original press release on ACCESS Newswire

ZeroPath Corp

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release

Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release

OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release

CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye